Compare IMMP & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | LAW |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 466.2M |
| IPO Year | N/A | 2021 |
| Metric | IMMP | LAW |
|---|---|---|
| Price | $2.63 | $8.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | ★ 1.8M | 283.2K |
| Earning Date | 02-22-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,306,742.00 | ★ $152,677,000.00 |
| Revenue This Year | N/A | $8.51 |
| Revenue Next Year | N/A | $7.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.28 | 6.33 |
| 52 Week Low | $1.32 | $3.31 |
| 52 Week High | $3.53 | $9.11 |
| Indicator | IMMP | LAW |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 63.35 |
| Support Level | $2.42 | $8.20 |
| Resistance Level | $2.86 | $8.72 |
| Average True Range (ATR) | 0.27 | 0.37 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 51.35 | 64.45 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.